Global Trial in APG2575 for Patients With CLL/SLL

Summary

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Timeline

Start

2023-12-20

Primary completion

2026-12-31

Completion

2027-10-31

Drugs

Indications